TNSN00034A1 - Derives de 2-aminopyridine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

Derives de 2-aminopyridine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number
TNSN00034A1
TNSN00034A1 TNTNSN00034A TNSN00034A TNSN00034A1 TN SN00034 A1 TNSN00034 A1 TN SN00034A1 TN TNSN00034 A TNTNSN00034 A TN TNSN00034A TN SN00034 A TNSN00034 A TN SN00034A TN SN00034 A1 TNSN00034 A1 TN SN00034A1
Authority
TN
Tunisia
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
novel
aminopyridine derivatives
Prior art date
Application number
TNTNSN00034A
Other languages
English (en)
Inventor
Adams Lowe John Iii
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN00034A1 publication Critical patent/TNSN00034A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)

Abstract

] L'INVENTION CONCERNE DES DERIVES DE 2- AMINOPYRIDINE DE FORMULE I : DANS LAQUELLE A, B, X, Y ET R1 REPRESENTENT DIVERS RADICAUX. ELLE CONCERNE EGALEMENT UN PROCEDE POUR LEUR PREPARATION ET DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS, INHIBANT L'ACTIVITE DES OXYDES NITRIQUES-SYNTHASES (NOS), POUR LE TRAITEMENT DE DIVERSES MALADIES, NOTAMMENT DU SYSTEME NERVEUX CENTRAL.
TNTNSN00034A 1999-02-25 2000-02-23 Derives de 2-aminopyridine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant TNSN00034A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12159799P 1999-02-25 1999-02-25

Publications (1)

Publication Number Publication Date
TNSN00034A1 true TNSN00034A1 (fr) 2005-11-10

Family

ID=22397690

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN00034A TNSN00034A1 (fr) 1999-02-25 2000-02-23 Derives de 2-aminopyridine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (44)

Country Link
US (2) US6211208B1 (fr)
EP (1) EP1155000B1 (fr)
JP (1) JP3825636B2 (fr)
KR (1) KR20010114213A (fr)
CN (1) CN1341099A (fr)
AP (1) AP2001002251A0 (fr)
AR (1) AR018979A1 (fr)
AT (1) ATE245143T1 (fr)
AU (1) AU767593B2 (fr)
BG (1) BG105855A (fr)
BR (1) BR0008569A (fr)
CA (1) CA2364719C (fr)
CO (1) CO5160241A1 (fr)
CR (1) CR6438A (fr)
CZ (1) CZ20013036A3 (fr)
DE (1) DE60003893T2 (fr)
DK (1) DK1155000T3 (fr)
DZ (1) DZ3017A1 (fr)
EA (1) EA003941B1 (fr)
EE (1) EE200100454A (fr)
ES (1) ES2200813T3 (fr)
GT (1) GT200000021A (fr)
HN (1) HN2000000016A (fr)
HR (1) HRP20010597A2 (fr)
HU (1) HUP0200163A3 (fr)
ID (1) ID29892A (fr)
IL (1) IL144308A0 (fr)
IS (1) IS6005A (fr)
MA (1) MA26721A1 (fr)
MX (1) MXPA01008671A (fr)
NO (1) NO20014095L (fr)
NZ (1) NZ512912A (fr)
OA (1) OA11841A (fr)
PA (1) PA8490901A1 (fr)
PE (1) PE20001482A1 (fr)
PL (1) PL350219A1 (fr)
PT (1) PT1155000E (fr)
SK (1) SK12022001A3 (fr)
SV (1) SV2002000026A (fr)
TN (1) TNSN00034A1 (fr)
TR (1) TR200102481T2 (fr)
WO (1) WO2000050400A1 (fr)
YU (1) YU58301A (fr)
ZA (1) ZA200106974B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049379A1 (en) * 1997-08-27 2001-12-06 Lowe John Adams 2-aminopyridines containing fused ring substituents
DK1155000T3 (da) * 1999-02-25 2003-10-13 Pfizer Prod Inc 2-aminopyridiner som indeholder sammensluttede ringsubstituenser
CN1426397A (zh) 2000-03-31 2003-06-25 欧洲凯尔特股份有限公司 氨基吡啶类化合物及其作为抗惊厥剂和钠通道阻滞剂的应用
US20040092741A1 (en) * 2002-11-08 2004-05-13 Pfizer Inc Substituted pyridines via boronic acid coupling
US8729107B2 (en) * 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
EP1567497B1 (fr) * 2002-12-06 2009-09-23 Purdue Research Foundation Pyridines destinees au traitement de tissus nerveux mammaliens leses
US20050192321A1 (en) * 2003-09-15 2005-09-01 Meythaler Jay M. Treatment of neuropathy with rapid release aminopyridine
WO2014138460A1 (fr) 2013-03-07 2014-09-12 Northwestern University Inhibiteurs de l'oxyde nitrique synthase neuronaux sélectifs à base de 2-aminopyridine
US10759791B2 (en) 2014-11-04 2020-09-01 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
WO2016073623A2 (fr) 2014-11-04 2016-05-12 Northwestern University Inhibiteurs d'oxyde nitrique synthase d'origine bactérienne et mammalienne
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018616A1 (fr) * 1994-12-12 1996-06-20 Merck & Co., Inc. 2-aminopyridines substituees utilisees comme inhibiteurs de synthase d'oxyde d'azote
JPH101435A (ja) * 1995-09-14 1998-01-06 Nippon Kayaku Co Ltd ２−アミノピリジン類を有効成分とする一酸化窒素合成酵素阻害剤
DE69728138T2 (de) * 1996-03-29 2004-09-16 Pfizer Inc. 6-phenylpyridinderivate
HN1997000027A (es) 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina
AU744313B2 (en) * 1997-02-10 2002-02-21 Pfizer Products Inc. 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines
HN1998000118A (es) * 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
HN1998000125A (es) * 1997-08-28 1999-02-09 Pfizer Prod Inc 2-aminopiridinas con sustituyentes alcoxi ramificados
DE69923448T2 (de) * 1998-06-03 2005-12-29 Pfizer Products Inc., Groton 2-aminopyridine mit kondensierten ringsubstituenten als stickstoff-oxid-synthase inhibitoren
DK1155000T3 (da) * 1999-02-25 2003-10-13 Pfizer Prod Inc 2-aminopyridiner som indeholder sammensluttede ringsubstituenser

Also Published As

Publication number Publication date
SV2002000026A (es) 2002-02-05
ID29892A (id) 2001-10-18
CN1341099A (zh) 2002-03-20
HUP0200163A3 (en) 2002-11-28
CR6438A (es) 2004-02-23
EA200100816A1 (ru) 2001-12-24
SK12022001A3 (sk) 2002-07-02
BR0008569A (pt) 2002-01-22
PT1155000E (pt) 2003-10-31
ES2200813T3 (es) 2004-03-16
NO20014095L (no) 2001-10-24
YU58301A (sh) 2004-05-12
CA2364719C (fr) 2006-07-04
CZ20013036A3 (cs) 2002-03-13
HUP0200163A2 (en) 2002-06-29
AP2001002251A0 (en) 2001-09-30
EA003941B1 (ru) 2003-10-30
CA2364719A1 (fr) 2000-08-31
EP1155000A1 (fr) 2001-11-21
NZ512912A (en) 2003-07-25
KR20010114213A (ko) 2001-12-31
IL144308A0 (en) 2002-05-23
DK1155000T3 (da) 2003-10-13
NO20014095D0 (no) 2001-08-23
PA8490901A1 (es) 2001-04-30
AU767593B2 (en) 2003-11-20
BG105855A (en) 2002-04-30
JP2002537381A (ja) 2002-11-05
ZA200106974B (en) 2002-10-14
HRP20010597A2 (en) 2002-08-31
EP1155000B1 (fr) 2003-07-16
AU2124300A (en) 2000-09-14
DE60003893D1 (de) 2003-08-21
US20010014689A1 (en) 2001-08-16
ATE245143T1 (de) 2003-08-15
IS6005A (is) 2001-07-13
CO5160241A1 (es) 2002-05-30
WO2000050400A1 (fr) 2000-08-31
JP3825636B2 (ja) 2006-09-27
HN2000000016A (es) 2001-02-02
PL350219A1 (en) 2002-11-18
US6211208B1 (en) 2001-04-03
US6372768B2 (en) 2002-04-16
MA26721A1 (fr) 2004-12-20
OA11841A (en) 2005-08-22
DE60003893T2 (de) 2004-02-05
PE20001482A1 (es) 2001-01-03
EE200100454A (et) 2002-12-16
GT200000021A (es) 2001-08-17
AR018979A1 (es) 2001-12-12
DZ3017A1 (fr) 2004-03-20
MXPA01008671A (es) 2002-03-14
TR200102481T2 (tr) 2002-01-21

Similar Documents

Publication Publication Date Title
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99155A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99073A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00028A1 (fr) Derives de quinoleine -2-one a substituant heteroaryle nouveaux procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97198A1 (fr) Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant
TNSN99253A1 (fr) Composes chimiques nouveaux modulateurs de ccr5, et compositions pharmaceutiques les contenant.
TNSN98019A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98150A1 (fr) Derives d'acides aryloxyarylsulfonylaminohydroxamiques ; procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99106A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN00104A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98154A1 (fr) Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant
TNSN96172A1 (fr) Composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98035A1 (fr) Atropisomeres de 3-aryl-4(3h)-quinazolinones, procede pour leur preparation et compositions les contenant
TNSN99169A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98024A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98022A1 (fr) DERIVES DE N-HYDROXY-β-SULFONYLPROPIONAMIDE, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT.
TNSN99236A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98194A1 (fr) Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00121A1 (fr) Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
TNSN98112A1 (fr) Composes dipeptidiques
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98066A1 (fr) Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26720A1 (fr) Composes nouveaux inhibiteurs de reabsorption de monoamines, procede pour leur preparation, et compositions pharmaceutiques les contenant.
TNSN00108A1 (fr) Derives d'erythromycine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant